公开(公告)号：US6132729A

公开(公告)日：2000-10-17

申请号：US9217

申请日：1998-01-20

Applicant: Philip E. Thorpe ,  Steven W. King ,  Boning Gao

Inventor： Philip E. Thorpe ,  Steven W. King ,  Boning Gao

IPC: A61K45/00 ,  A61K38/00 ,  A61K47/48 ,  A61P7/02 ,  A61P35/00 ,  A61K39/00 ,  A61K39/395 ,  C07K14/00 ,  C07K35/14

CPC classification number: A61K47/48423 ,  A61K47/48292 ,  Y10S514/834 ,  Y10S530/827 ,  Y10S530/829

Abstract: The invention embodies the surprising discovery that Tissue Factor (TF) compositions and variants thereof specifically localize to the blood vessels within a vascularized tumor following systemic administration. The invention therefore provides methods and compositions comprising coagulation-deficient Tissue Factor for use in effecting specific coagulation and for use in tumor treatment. The TF compositions and methods of present invention may be used alone, as TF conjugates with improved half-life, or in combination with other agents, such as conventional chemotherapeutic drugs, targeted immunotoxins, targeted coaguligands, and/or in combination with Factor VIIa (FVIIa) or FVII activators.

Abstract translation: 本发明体现了惊人的发现：组织因子（TF）组合物及其变体在全身给药后特异性定位于血管化肿瘤内的血管。 因此，本发明提供了用于实现特异性凝结和用于肿瘤治疗的凝血缺陷组织因子的方法和组合物。 本发明的TF组合物和方法可以单独使用，作为具有改善的半衰期的TF缀合物，或与其它试剂（例如常规化学治疗药物，靶向免疫毒素，靶向凝固配体）和/或与因子VIIa组合 FVIIa）或FVII激活剂。